Compass Pathways Plc (CMPS)
13.23
-0.01
(-0.08%)
USD |
NASDAQ |
Sep 02, 16:00
13.20
-0.03
(-0.23%)
After-Hours: 20:00
Compass Pathways Research and Development Expense (TTM) : 112.68M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 112.68M |
| March 31, 2026 | 114.15M |
| December 31, 2025 | 118.72M |
| September 30, 2025 | 120.70M |
| June 30, 2025 | 126.81M |
| March 31, 2025 | 125.21M |
| December 31, 2024 | 119.10M |
| September 30, 2024 | 114.63M |
| June 30, 2024 | 102.76M |
| March 31, 2024 | 93.54M |
| December 31, 2023 | 87.87M |
| September 30, 2023 | 80.43M |
| Date | Value |
|---|---|
| June 30, 2023 | 72.89M |
| March 31, 2023 | 68.79M |
| December 31, 2022 | 64.86M |
| September 30, 2022 | 58.52M |
| June 30, 2022 | 56.81M |
| March 31, 2022 | 52.36M |
| December 31, 2021 | 43.99M |
| September 30, 2021 | 34.92M |
| June 30, 2021 | 29.66M |
| March 31, 2021 | 25.05M |
| December 31, 2020 | 23.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Silence Therapeutics Plc | 43.54M |
| Biodexa Pharmaceuticals Plc | 5.234M |
| NuCana Plc | 12.59M |
| Mereo BioPharma Group Plc | 14.98M |
| HemoGenyx Pharmaceuticals Plc | -- |